DUBLIN, Jan. 3, 2017 /PRNewswire/ -- Jazz
Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company
will be webcasting its corporate presentation at the 35th Annual
J.P. Morgan Healthcare Conference in San
Francisco, CA.
Bruce Cozadd, chairman and chief
executive officer, will provide an overview of the company and
provide a business and financial update at the conference on
Monday, January 9, 2017 at
9:00 a.m. PST / 5:00 p.m. GMT.
A live audio webcast of the presentation may be accessed from
the Investors section of the Jazz Pharmaceuticals website at
www.jazzpharmaceuticals.com. Please connect to the website prior to
the start of the presentation to ensure adequate time for any
software downloads that may be necessary to listen to the
webcast.
An archive of the webcast will be available for at least one
week following the presentation on the Investors section of the
company's website at www.jazzpharmaceuticals.com.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc
(Nasdaq: JAZZ) is an international biopharmaceutical company
focused on improving patients' lives by identifying, developing and
commercializing meaningful products that address unmet medical
needs. The company has a diverse portfolio of products and product
candidates, with a focus in the areas of sleep and
hematology/oncology. In these areas, Jazz Pharmaceuticals markets
Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase
Erwinia chrysanthemi) and Defitelio® (defibrotide sodium) in
the U.S. and markets Erwinase® and Defitelio® (defibrotide) in
countries outside the U.S. For more information, please visit
www.jazzpharmaceuticals.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-present-at-the-jp-morgan-healthcare-conference-on-january-9-300384871.html
SOURCE Jazz Pharmaceuticals plc